Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Suicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    362 result(s) found for: Suicide. Displaying page 4 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-002787-27 Sponsor Protocol Number: 20190530 Start Date*: 2021-03-15
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From ...
    Medical condition: Subjects with active Behçet’s Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001884-38 Sponsor Protocol Number: I5Q-MC-CGAJ Start Date*: 2015-12-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine.
    Medical condition: Episodic or chronic migraine headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004611-38 Sponsor Protocol Number: AV002 Start Date*: 2018-10-09
    Sponsor Name:Bond Avillion 2 Development LP
    Full Title: A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with mo...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-022744-21 Sponsor Protocol Number: AB08003 Start Date*: 2013-06-05
    Sponsor Name:AB Science
    Full Title: A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepr...
    Medical condition: mood disorders associated to major depression or dysthymic disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10013982 Dysthymic disorder PT
    16.0 10037175 - Psychiatric disorders 10012374 Depressed mood PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001444-66 Sponsor Protocol Number: VESPA Start Date*: 2018-09-12
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: ASSESSING TOLERABILITY AND EFFICACY OF VORTIOXETINE VERSUS SSRIs IN ELDERLY PATIENTS WITH DEPRESSION: A PRAGMATIC, MULTICENTER, OPEN-LABEL, PARALLEL-GROUP, SUPERIORITY, RANDOMIZED TRIAL
    Medical condition: major depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002482-17 Sponsor Protocol Number: TAK-935-3003 Start Date*: 2022-05-09
    Sponsor Name:Takeda Development Center Americas, Inc
    Full Title: A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or ...
    Medical condition: Dravet Syndrome (DS) Lennox-Gastaut Syndrome (LGS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) Outside EU/EEA DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004903-33 Sponsor Protocol Number: IBM4809 Start Date*: 2018-06-18
    Sponsor Name:Orphazyme A/S
    Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial
    Medical condition: Sporadic Inclusion Body Myositis (sIBM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10075052 Sporadic inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001523-39 Sponsor Protocol Number: D1050300 Start Date*: 2013-11-08
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000469-18 Sponsor Protocol Number: IP2018CS01 Start Date*: 2020-06-26
    Sponsor Name:Initiator Pharma
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients
    Medical condition: Male patients with a diagnosis of mild to moderate depression and ED as determined from the Hamilton depression scale score of 7 to 23 and International Index of Erectile Function (IIEF-5) score of...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004715-40 Sponsor Protocol Number: BRU-VCN-2017 Start Date*: 2018-07-04
    Sponsor Name:Fundació Hospital Universitari Vall d’Hebron-Institut de Recerca (VHIR)
    Full Title: An effectiveness and safety study of Varenicline for smoking cessation in hospitalized patients with psychiatric disorders.
    Medical condition: Smoking cessation in hospitalized patients with psychiatric disorders.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003745-14 Sponsor Protocol Number: D1448C00005 Start Date*: 2006-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monothe...
    Medical condition: Maintenance treatment of patients with Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003615-28 Sponsor Protocol Number: SPD489-209 Start Date*: 2012-12-21
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003369-16 Sponsor Protocol Number: GWAP19030 Start Date*: 2020-06-02
    Sponsor Name:GW Research Ltd.
    Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate...
    Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004885-32 Sponsor Protocol Number: DOBINeuro Start Date*: 2019-08-30
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
    Full Title: THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (D/L/A) TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) IN PATIENTS WITH SUPPRESSED VIRAL LOAD ON NEUROPSYCHIATRIC SIDE E...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003271-18 Sponsor Protocol Number: GWSP20105 Start Date*: 2021-06-07
    Sponsor Name:GW Pharma Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
    Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004685-10 Sponsor Protocol Number: PD-1105 Start Date*: 2019-01-11
    Sponsor Name:Voyager Therapeutics, Inc.
    Full Title: A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuatio...
    Medical condition: Patients with Parkinson's Disease with motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005164-26 Sponsor Protocol Number: DS5565-A-E312 Start Date*: 2014-12-19
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia
    Medical condition: DS-5565 is being developed for the treatment of pain associated with fibromyalgia (FM).
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) AT (Completed) SK (Completed) EE (Completed) CZ (Completed) ES (Completed) LT (Completed) HU (Completed) LV (Completed) PT (Completed) SI (Completed) FI (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016529-32 Sponsor Protocol Number: GWCA0999 Start Date*: 2010-04-02
    Sponsor Name:GW Pharma Ltd
    Full Title: A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled pers...
    Medical condition: Pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) HU (Completed) DE (Completed) PL (Completed) LT (Completed) LV (Completed) EE (Prematurely Ended) BG (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-004420-30 Sponsor Protocol Number: CL3-95008-002 Start Date*: 2018-10-04
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002292-41 Sponsor Protocol Number: H8Y-MC-HBDF Start Date*: 2011-11-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients with DSM-IV-TR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 17:23:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA